Cancers in MSH6 mutation carriers occur later than those in the MLH1 or MSH2 PV/LPVs, with cumulative CRC incidences at 40 of 2.5% (females) and 6.3% (males), and 2.3% for endometrial cancer. This evidence concerns the gene MSH2 and endometrial cancer.